On Jul. 21, 2021, Humanigen announced its development and commercialization partners for South Korea and the Philippines, Telcon RF Pharmaceutical and KPM Tech, have received approval from South Koreaﾒs MFDS to conduct a Phase 1 clinical study of lenzilumab, which may support potential use in the treatment of hospitalized COVID-19 patients.